![Naloxone doses in injection and nasal spray form](https://www.uc.edu/news/articles/2023/04/n21164586/jcr:content/image.img.cq5dam.thumbnail.500.500.jpg/1681746326741.jpg)
Memphis news: Fighting overdose deaths with a vending machine
Memphis, Tennessee television news station Action News 5 recently highlighted the harm reduction vending machine program run by Cincinnati nonprofit Caracole in partnership with the University of Cincinnati.
The machine provides an anonymous way for anyone in the community to access free supplies including naloxone, the drug that can be used to reverse an overdose, safe injection kits, safe smoking kits and more.
"We do not believe that providing supplies to keep people safe, to keep people from overdosing and to keep people from contracting infectious diseases, enables them in any way,” said Suzanne Bachmeyer, Caracole director of prevention.
Since its implementation, naloxone from the machine has been used more than 1,100 times to reverse an overdose, according to Daniel Arendt, PharmD, assistant professor in UC’s James L. Winkle College of Pharmacy and co-chair of the pain stewardship committee for UC Health.
Watch the Action News 5 report.
Wilmington, North Carolina's Port City Daily also highlighted the UC-Caracole partnership in a story about efforts to bring a harm reduction vending machine to the Wilmington area. Read the Port City Daily story.
Read a Kiosk Marketplace story on the program.
Read more about the program and research.
Featured photo at top of naloxone doses courtesy of Unsplash.
Related Stories
Discover Magazine: Why bacteria are the new disease fighters
January 10, 2022
UC's Dr. Nalinikanth Kotagiri was featured in a Discover Magazine article focused on the use of bacteria to fight diseases including cancer.
Journal-News: UC researchers engineer bacteria to weaken cancer cell walls
November 22, 2021
University of Cincinnati researchers from the College of Pharmacy were featured in a Journal-News article detailing the development of a new probiotic bacteria designed to break down cancer cell walls.
Law & Crime: Medical uses and dosages of fentanyl
February 23, 2022
The University of Cincinnati's Dr. Dan Arendt was featured in a Law & Crime television segment on the topic of medical uses of fentanyl.
55KRC: Grants aid UC research of pediatric brain tumors
March 14, 2022
55KRC featured the University of Cincinnati's Dr. Timothy Phoenix on the Simply Medicine program, discussing his research into treatments for diffuse midline glioma, a deadly pediatric brain tumor.
Medical Xpress: Researchers identify new target to treat pediatric brain tumors
February 4, 2022
Medical Xpress highlighted the work of the University of Cincinnati's Timothy Phoenix and his colleagues who have identified the role of a key gene linked to pediatric diffuse midline gliomas, a deadly brain tumor.
HuffPost: Things you didn't know pharmacists could help with
March 23, 2022
The University of Cincinnati's Michael Hegener, PharmD, was featured in a HuffPost article about different health issues pharmacists can help patients with beyond filling prescriptions.
Local 12: Pharmacies adjusting hours due to staffing issues
April 29, 2022
The University of Cincinnati's Jill Boone was featured in a Local 12 story on the impact of staffing issues at local pharmacies.
WVXU: Exploring the under-regulated dietary supplements industry
August 17, 2022
The University of Cincinnati's Michael Hegener, PharmD, was a panelist on WVXU's Cincinnati Edition discussing the under-regulated dietary supplements industry.
Drug Discovery News: Silence in healthy cells makes FOXR2 a potential cancer target
April 7, 2023
Drug Discovery News highlighted research coauthored by the University of Cincinnati's Timothy Phoenix that found a gene called FOXR2 is abnormally expressed in more than 70% of cancer types sampled and could be a potential target for new treatments.
Physics World: Engineered bacteria attract cancer-killing radioisotopes into tumors
April 14, 2023
Physics World highlighted research led by the University of Cincinnati's Nalinikanth Kotagiri that shows a proof of concept for using engineered bacteria as an adapter to deliver targeted radionuclide treatment to tumors.